4 5 November 2011, Lisbon, Portugal

Transcription

1 11th International AMD and Retina Congress 4 5 November 2011, Lisbon, Portugal

2 1 ESASO 11th International AMD and Retina Congress Content 2 Welcome by the Organising Committee 3-4 Scientific Programme: Friday, 4 November Scientific Programme: Saturday, 5 November Session 1: Perspectives on the diagnosis and treatment of diabetic macular edema Chairs: Prof. Paul Mitchell, Australia and Prof. José Cunha-Vaz, Portugal 7 Session 2: Prognostic markers in retinal diseases Chairs: Prof. Gisèle Soubrane, France and Dr. Adrian Koh, Singapore 8 Session 3: Recent developments in RVO management Chairs: Prof. Michael Larsen, Denmark and Prof. Anat Loewenstein, Israel 9 Session 4: Effective diagnosis and treatment of Age-related Macular Degeneration Chairs: Prof. Neil M Bressler, USA and Prof. Francesco Bandello, Italy 10 Session 5: Clinical management of other retinal disorders Chairs: Prof. Gabriel Coscas, France and Dr. Marco Zarbin, USA 11 Session 6: Other retinal challenges Chairs: Prof. Borja Corcóstegui, Spain and Prof. Antonio Capone, USA Faculty 20 Floorplan 21 Thank you from ESASO Delegate countries 22 Organisation ESASO would like to sincerely thank Novartis Pharma AG for supporting the 11th AMD and Retina Congress with an unrestricted educational grant. The event has been granted 9 European CME credits.

3 ESASO 11th International AMD and Retina Congress 2 Welcome by the Organising Committee Dear Congress Delegate, On behalf of ESASO s Executive Board, we are delighted to welcome you to the 11th AMD and Retina Congress in Lisbon on 4 5 November Our esteemed Scientific Committee has engaged distinguished international speakers to develop a forward-thinking, dynamic and interactive scientific programme, which includes: 24 Plenary presentations 3 Discussion-based sessions including 6 plenary presentations and 17 case-based panel discussions 5 Meet-the-Expert sessions Poster exhibition ESASO Graduation Ceremony We would like to thank the Scientific Committee for their input to the programme, and the session chairs for their assistance in the organization of each session. The Scientific Committee is chaired by Francesco Bandello (Italy), and includes Neil M Bressler (USA), and José Cunha-Vaz (Portugal), assisted by the congress scientific co-ordinators Maurizio Battaglia Parodi (Italy) and Bruno Falcomatá (Italy). We welcome you to a fantastic city which is much more than just a convention location. The blend of Lisbon s unique poetry with the rational sense of medicine allows for an unforgettable meeting experience. The congress venue offers great facilities for delegates and speakers, and seduces with a magnificent view over the river Tagus. We are confident that the 11th AMD and Retina Congress will continue to build upon the quality that ESASO have established during previous congresses and we wish you an enjoyable and informative stay in Lisbon. With our best regards, Yours Borja Corcostegui Professor and President, Institutuo de Microcirurgía Ocular (IMO), Barcelona, Spain Francesco Bandello Professor and Chairman, Department of Ophthalmology, University Vita-Salute Scientific Institute San Raffaele, Milan, Italy Giuseppe Guarnaccia President, ESASO Foundation, Director III Surgery Department at BMM Hospital, Reggio Calabria, Italy

4 3 ESASO 11th International AMD and Retina Congress Scientific Programme Friday, 4 November :45 Opening Ceremony Prof. Francesco Bandello, Italy Prof. Borja Corcóstegui, Spain Dr. Giuseppe Guarnaccia, Italy 08:55 Welcome to Lisboa Prof. José Cunha-Vaz, Portugal SESSION 1 Perspectives on the diagnosis and treatment of diabetic macular edema Chairs: Paul Mitchell, Australia Prof. José Cunha-Vaz, Portugal 09:00 09:07 DME Classification Prof. José Cunha-Vaz, Portugal 09:08 09:15 Evidence for Treatment Prof. Paul Mitchell, Australia 09:15 Discussion topic 1 Poor Glycaemic Compensation Prof. Paolo Lanzetta, Italy 09:30 Discussion topic 2 Extensive Macular Non-perfusion Prof. Gabriele Lang, Germany 09:45 Discussion topic 3 Cataract Surgery and DME Dr. David Pelayes, Argentina 10:00 Discussion topic 4 DME in Proliferative Diabetic Retinopathy Prof. Alain Gaudric, France 10:15 Discussion topic 5 Pseudophakes with DME Prof. Francesco Boscia, Italy 10:30 Discussion topic 6 Vitrectomy or Microplasmin in DME Prof. Athanasios Nikolakopoulos, Greece with Vitreomacular Traction 10:45 COFFEE BREAK SESSION 2 Prognostic markers in retinal diseases Chairs: Prof. Gisèle Soubrane, France Dr. Adrian Koh, Singapore 11:15 Prognostic indicators in macular edema due to DME Prof. Paolo Lanzetta, Italy 11:30 Prognostic indicators in macular edema due to RVO Prof. Rufino Silva, Portugal 11:45 Prognostic indicators in AMD Dr. Adrian Koh, Singapore 12:00 Correlation genotype-phenotype Prof. Gisèle Soubrane, France 12:15 New tools for remote monitoring of AMD Dr. Ian Pearce, UK 12:30 LUNCH 13:00 14:00 Meet-the-expert sessions Economics in anti-vegf therapy: how to optimize results and reduce overall costs Optimizing safety of intravitreal delivery: examining the evidence Management of DME Treatment of Leber-Coats and other congenital retinal vasculopathies Medical and surgical management of RVO Prof. Paul Mitchell, Australia Prof. Gabriele Lang, Germany Dr. Jordi Monés, Spain Dr. Peter Kaiser, USA Prof. Francesco Bandello, Italy Prof. Alain Gaudric, France Dr. Antonio Capone, USA Prof. Borja Corcóstegui, Spain Dr. Ian Pearce, UK Prof. Francesco Boscia, Italy

5 ESASO 11th International AMD and Retina Congress 4 SESSION 3 Recent developments in RVO management Chairs: Prof. Michael Larsen, Denmark Prof. Anat Loewenstein, Israel 14:15 14:45 2nd ESASO Graduation Ceremony 14:45 Clinical Patterns of RVO Prof. Anat Loewenstein, Israel 14:53 Clinical Trials and Guidelines Prof. Michael Larsen, Denmark 15:00 Discussion topic 1 Surgery: Is there still a role? Prof. José Garcia-Arumi, Spain 15:20 Discussion topic 2 Macular edema from BRVO Dr. Luis Arias, Spain 15:40 Coffee break 16:10 Discussion topic 3 Extensive non-perfused CRVO Prof. Bora Eldem, Turkey 16:30 Discussion topic 4 Ocular neovascularisation related to RVO Dr. Jordi Monés, Spain 16:50 Discussion topic 5 Neovascular glaucoma Dr. David Pelayes, Argentina 17:10 EUROLAM presentation Dr. David Pelayes, Argentina 17:15 Chair Summary and Close Welcome to Lisbon

6 5 ESASO 11th International AMD and Retina Congress Scientific Programme Saturday, 5 November 2011 SESSION 4 Effective diagnosis and treatment of AMD Chairs: Prof. Neil M Bressler, USA Prof. Francesco Bandello, Italy 08:30 Multicentre Trials Prof. Neil M Bressler, USA 08:37 Practical Management Prof. Francesco Bandello, Italy 08:45 Discussion topic 1 Safety Dr. Peter Kaiser, USA 09:00 Discussion topic 2 Extrafoveal and Juxtafoveal CNV Prof. Michael Larsen, Denmark 09:15 Discussion topic 3 Radiation Therapy Prof. Leonidas Zografos, Switzerland 09:30 Discussion topic 4 The value of patient registries Prof. Paul Mitchell, Australia 09:45 Discussion topic 5 Geographic atrophy of the RPE in AMD Dr. Susan B Bressler, USA 10:00 Discussion topic 6 New Treatments for Dry AMD: Dr. Marco Zarbin, USA A Pathway-Based Appraisal 10:15 Poster Awards 10:30 COFFEE BREAK SESSION 5 Clinical management of other retinal disorders Chairs: Prof. Gabriel Coscas, France Dr. Marco Zarbin, USA 11:00 Clinical aspects and treatment of CNV complicating angioid streaks Dr. Bruno Falcomatà, Italy 11:10 Clinical aspects and treatment of idiopathic macular telangiectasis Dr. Rafael Navarro, Spain 11:20 Classification and management of CSCR Prof. Rufino Silva, Portugal 11:30 Management of Myopic CNV Dr. Maurizio Battaglia Parodi, Italy 11:40 Role of anti-vegf therapy in Paediatric retinal diseases Dr. Antonio Capone, USA (ROP, Coates disease, CNV) SESSION 6 Other Retinal Challenges Chairs: Dr. Antonio Capone, USA Prof. Borja Corcóstegui, Spain 11:50 Treatment of neovascular AMD with large macular haemorrhage Dr. Carl Claes, Belgium 12:00 Macular schisis in pathologic myopia Prof. Won Ki Lee, South Korea 12:10 Retinal angiomatous proliferation management Dr. Antonio Capone, USA 12:20 Vitelliform lesions Dr. Giuseppe Querques, France 12:30 Symptomatic vitreomacular adhesions Prof. Alain Gaudric, France 12:40 Inflammatory CNV Dr. Ângela Carneiro, Portugal 12:50 13:00 Close of Meeting Prof. Francesco Bandello, Italy

7 ESASO 11th International AMD and Retina Congress 6 Session 1 Perspectives on the diagnosis and treatment of diabetic macular edema Chairs: Prof. Paul Mitchell, Australia and Prof. José Cunha-Vaz, Portugal The availability of proven treatments which deliver improved visual acuity outcomes for patients with DME, as well as a greater understanding of key disease features have provided significant benefit to clinicians and patients in recent years. A classification of Diabetic Macular Edema based on non-invasive objective examination by OCT will be presented. The proven efficacy and safety of ranibizumab for the treatment of DME, and its subsequent approval, changed the management of DME in clinical practice. Additionally, recently published outcomes from the Phase II DA VINCI study with VEGF Trap-Eye demonstrated significant efficacy in patients with DME. It is hoped that ongoing Phase III studies may provide further favourable outcomes. However, clinical challenges remain and this Session will highlight some of the most pertinent issues associated with DME through case-based discussions and shared experiences. The role of good systemic control in patients with DME will be highlighted, after which, a variety of pathologies associated with DME and how such cases may be optimally managed in clinical practice will be considered by the Panel. These include extensive macular non-perfusion, cataracts, DME in proliferative diabetic retinopathy, and pseudophakes with DME. Finally, the use of vitrectomy or microplasmin in DME with vitreomacular traction will be discussed. Paul Mitchell Department of Ophthalmology, University of Sydney, Sydney, Australia Paul Mitchell is Professor of Ophthalmology at the University of Sydney and Director of Ophthalmology for the Sydney West Area Health Service, Australia. His clinical work focuses on managing AMD, diabetic and other vascular retinopathies, and on systemic diseases and their effects on the eye. He has a strong interest in the application of evidence-based medicine in ophthalmology, particularly in the area of new therapies for AMD and DME. Professor Mitchell has made significant contributions in the fields of public health and ophthalmic epidemiology via the landmark Blue Mountains Eye Study, which has already yielded over 350 international publications. He is a clinical examiner for the Royal Australian and New Zealand College of Ophthalmologists. Professor Mitchell has published over 650 peer-reviewed scientific papers and is on the editorial boards of British Journal of Ophthalmology and Eye, as well as being a reviewer for key journals in the field of ophthalmology and general medicine. He is currently Vice President of ARVO and member of the ARVO Board of Trustees. José Cunha-Vaz Coimbra University Hospital, Coimbra, Portugal José Cunha-Vaz, M.D., Ph.D. is Emeritus Professor of Ophthalmology, President of the Association for Innovation and Biomedical Research on Light and Image, a not-for-profit Clinical Research Organization. He is Chief Editor of Ophthalmologica and Chair of the European Vision Institute Clinical Research Network, EVICR.net. In 1978, Dr. Cunha-Vaz moved to the United States to become a full-time Professor of Ophthalmology and Director of the Retina Service at the University of Illinois at Chicago until his final return to Coimbra. Dr. Cunha-Vaz s work has included laboratory and clinical research in retina and intraocular fluids with special emphasis on blood-retinal barriers and diabetic retinopathy. He initiated clinical vitreous fluorometry and multimodal macular mapping. Dr. Cunha-Vaz serves on the boards of many scientific journals, has published more than 44 books and book chapters and 410 peer-reviewed journal articles.

8 7 ESASO 11th International AMD and Retina Congress Session 2 Prognostic markers in retinal diseases Chairs: Prof. Gisèle Soubrane, France and Dr. Adrian Koh, Singapore Prognostic indicators can be helpful tools for guiding clinical management of retinal diseases. Indicators vary between diseases; however there are common factors such as extent of ischemia, duration of macular edema, OCT features, and baseline BCVA that are important to consider when assessing the overall prognosis of each patient. In this session, the panel will consider prognostic indicators in macular edema due to either DME or RVO, followed by those indicative of disease outcomes in AMD. Genetic markers and their influence on disease progression are likely to play a greater role in clinical management of retinal diseases in the future. Bearing this in mind, we will consider correlations between genotypes and phenotypes in retinal disease and the benefits greater understanding of such characteristics may confer over time. We hope the presentations within this Session stimulate interesting and lively discussions as we assess how new clinical findings may aid our understanding and treatment of ocular conditions. Gisèle Soubrane Eye University of Créteil, Université Paris Est Créteil XII, Paris, France Gisèle Soubrane is Emeritus Professor of the Department of Ophthalmology at the Eye University of Créteil Université Paris Est Creteil XII. Her research focuses on improvements in the diagnosis of AMD, pathogenesis and experimental models of AMD. Her department has participated in the evaluation of all new therapeutic approaches and pharmacological interventions for CNV, while her achievements have included describing occult CNV and identifying the reticular pseudo drusen and chorioretinal anastomosis. Gisèle Soubrane has served as General Secretary of the French Society of Ophthalmology, General Secretary and President of the European Board of Ophthalmology, and President and honorary member of the European Societies for Vision and Eye Research. She has been a Board member of EURETINA since its foundation, and has been elected to the European Academia. Her work has been recognised by the American Academy of Ophthalmology, and she has also been elected as the International Board Member of the Macula Society. She holds advisory positions on several national and international ophthalmology journals and nominating committees. Gisèle Soubrane has received a doctorate honoris causa from the University of Ulm, the Herman Wacker Prize from the Club Jules Gonin, the Junius Kuhnt Medal from the University of Bonn, and recently the Jules François Medal from the the International Council of Ophthalmology. Her outstanding contributions have also been recognised by the French state with the award of the Légion d Honneur. Adrian Koh Eye & Retina Surgeons, CamdenMedical Centre, Singapore Adrian Koh is Founding Partner and Senior Consultant at the Eye & Retina Surgeons, Camden Medical Centre. He is also Visiting Consultant to the Vitreoretinal Service, Singapore National Eye Centre and the Eye Institute, Tan Tock Seng Hospital. Dr Koh completed fellowships in Medical Retina at Moorfields Eye Hospital and the Institute of Ophthalmology and at the Jules Stein Eye Institute. He is Past President of the Singapore Society of Ophthalmology, Vice-President of the International Retinal Foundation and the Founding Chairman and Honorary Adviser to the Retinitis Pigmentosa Society of Singapore. He is also a member of Retina International, the Asia-Pacific Retinal Advisory Board and the Asia-Pacific Vitreoretinal Society. Dr Koh was one of the first surgeons to introduce PDT in the Asia-Pacific region, and has pioneered both anti-vegf and combination therapy for patients with AMD. He has authored or edited many publications in the field of ophthalmology, and has received numerous prestigious awards.

9 ESASO 11th International AMD and Retina Congress 8 Session 3 Recent developments in RVO management Chairs: Prof. Michael Larsen, Denmark and Prof. Anat Loewenstein, Israel The management of retinal vein occlusion (RVO) has evolved dramatically during the last few years. Numerous multicentre, well-controlled randomized clinical trials have proven the efficacy of a variety of treatments for both central and branch RVO. It has generally been shown in many different trials that earlier treatment for these conditions harbours a better prognosis for visual acuity, and that the concept of a 3-month wait prior to initiation of treatment should be challenged. It has also been shown that various treatments may be beneficial in vein occlusion even in long-standing cases with chronic macular edema. For patients with RVO, it has been shown that treatment with anti-vegf agents, such as ranibizumab and bevacizumab, as well as treatment with steroids, both intravitreally and implanted in a long-lasting device, increases the chances of improving visual acuity. Additionally, surgical treatment, such as vitrectomy and/or chorioretinal anastomosis, still plays a role. The treatment regimen of the individual patient should take into consideration the mode of delivery, frequency of administration, side-effects and efficacy results, and should be tailored to the individual patient accordingly. Michael Larsen Department of Ophthalmology, Glostrup Hospital, Copenhagen, Denmark Michael Larsen is Professor of Clinical Ophthalmology at the University of Copenhagen and the Glostrup Hospital and National Eye Clinic of the Kennedy Center in Copenhagen. He graduated from the Medical School of the University of Copenhagen in He became a Doctor of Medical Science in 1993 and has been Director of the Macula Service within the Department of Ophthalmology at Glostrup Hospital since Professor Larsen has carried out clinical and experimental research in retinopathy and noninvasive techniques for assessment of retinal function and structure. His research focuses on the relation between function, metabolism, and perfusion in the retina under various types of metabolic challenges, including hypoperfusion, hypoxia, and unstable glycemia. Anat Loewenstein Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Faculty of Medicine, Tel Aviv University, Tel Aviv, and Director of the Department of Ophthalmology at the Tel Aviv Medical Center in Tel Aviv, Israel. After medical studies at the Hebrew University in Jerusalem and residency in the Department of Ophthalmology at the Tel Aviv Medical Center, she completed her fellowship in retinal vascular diseases and vitreoretinal surgery at the Wilmer Eye Institute, Johns Hopkins University Hospital in Baltimore, MD, USA. Professor Loewenstein s main areas of expertise are AMD, including early detection and treatment modalities, RVO and the investigation of drug toxicity to the retina. She has also led the development of model technology for early detection of macular degeneration. She has published numerous publications in peer-reviewed journals and ophthalmology textbooks. As a member of several national and international ophthalmological societies, she participates in several national and international meetings each year, frequently as an invited speaker.

10 9 ESASO 11th International AMD and Retina Congress Session 4 Effective diagnosis and treatment of Age-related Macular Degeneration Chairs: Prof. Neil M Bressler, USA and Prof. Francesco Bandello, Italy Several RCTs provided definitive evidence that monthly ranibizumab resulted in superior visual acuity outcomes 2 years compared with sham or verteporfin PDT. Given the logistical challenges of providing monthly treatment, the costs of the treatment, and the rare, but not zero, risk of endophthalmitis, a next logical step was to determine if less frequent dosing or similar medications could provide equivalent visual acuity results safely. Quarterly ranibizumab, while superior to no treatment, does not appear to be as effective as monthly treatment. However, both ranibizumab PRN with every 4 week evaluations (as given in CATT) and VEGF Trap every two months at fixed intervals following 3 monthly injections appear to provide equiva- lent results safely. Bevacizumab every 4 weeks appears to provide equivalent visual acuity results to ranibizumab every 4 weeks up to one year, although bevacizumab PRN (as given in CATT) has not been shown to provide equivalent visual acuity results to ranibizumab every 4 weeks, and an increased risk of systemic SAEs along with challenges with compounding bevacizumab require further study. This Session also will review the potential expanding role of anti-vegf drugs for CNV in extrafoveal locations, radiation therapy, tools for remote monitoring, the value of patient registries, and the management of geographic atrophy in AMD. Neil M Bressler Wilmer Eye Institute, John Hopkins Hospital, Baltimore, MD, USA Neil Bressler is Chief of the Retina Division at the Wilmer Eye Institute at Johns Hopkins University School of Medicine and has an endowed chair as the inaugural James P Gills Professor of Ophthalmology. His main research interests have been collaborative efforts in clinical trials of common retinal diseases, including AMD and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicentre RCTs and authored over 265 peer-reviewed publications. Currently, as Chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, he has extensive involvement regarding guidelines, policies, protocol development and implementation to facilitate Network operations in an open and transparent fashion. Dr Bressler also chairs the NEI s Data and Safety Monitoring Committee for intramural clinical trials and the FDA s Ophthalmic Devices Panel. Beyond ophthalmology, he chairs the Johns Hopkins University School of Medicine s Committee on Outside Interests and is a member of the Board of Trustees for the Interlochen Center for the Arts in Michigan. Francesco Bandello Scientific Institute San Raffaele Milan, Italy Francesco Bandello is Professor at the Scientific University Institute San Raffaele, Milan, Italy. He is President Elect of EURETINA and Vice-President of EuroLam. He is also Associate Editor of the European Journal of Ophthalmology, and a former board member of the Jules Gonin Club and Macula Society. He is a board member of EVER and a member of the Academia Ophthalmologica Internationalis, Academia Ophthalmologica Europea and Accademia Nazionale di Medicina. Professor Bandello has served as a peer reviewer for grant applications for the NEI since 2006 and has authored or co-authored over 140 articles, which are mainly related to retinal diseases.

11 ESASO 11th International AMD and Retina Congress 10 Session 5 Clinical management of other retinal disorders Chairs: Prof. Gabriel Coscas, France and Dr. Marco Zarbin, USA Vision loss associated with many retinal disorders is often the result of CNV-induced changes and macular edema. It is imperative that treatment of complications associated with substantial vision loss is initiated as early as possible in order to restore or improve visual acuity. Various therapies are employed in clinical practice for the treatment of retinal disorders such as CNV associated with angioid streaks, myopic CNV and CSCR; these include, but are not limited to, anti-vegf agents and verteporfin PDT. The role of combination therapy for the treatment of CNV associated with retinal disorders has been investigated in small, short-term studies with generally favourable outcomes. Long-term RCTs are required to to provide evidence of efficacy and whether vision improvements are sustained over time. A number of case studies have reported vision improvements with anti-vegf agents for the treatment of CNV and macular edema in patients with idiopathic macular telangiectasia. However, the infrequent presentation of this disorder in clinical practice means that optimal treatment and long-term outcomes remain unknown. The clinical aspects and current treatment of this condition will be highlighted as part of this Session. Lastly, we will be guided through the role of anti-vegf therapies specifically for use in paediatric retinal diseases and the associated vision outcomes in this patient population. Gabriel Coscas Eye University of Créteil Université Paris XII, Paris, France Gabriel Coscas was trained at the University of Paris, Paris, France. In 1970, he established the Department of Ophthalmology in Créteil (University Paris XII, France) where he served as Professor of Ophthalmology and Chairman until He is currently Emeritus Professor at the same university. Professor Coscas devoted most of his research activity to macular diseases and organised the first RCT on macular photocoagulation for AMD in France. He founded and is President of the French Retina Society. He has authored or co-authored over 450 peer-reviewed papers and many books, including Atlas of Indocyanine Green Angiography and Optical Coherence Tomography in Age-Related Macular Degeneration. Professor Coscas has received numerous awards and was honoured as the first recipient of the Gabriel Coscas Lecture in He is a founding member of the Global Alliance against Trachoma at the WHO. Marco Zarbin Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark, NJ, USA Marco Attilio Eugenio Zarbin, M.D., Ph.D., F.A.C.S. received a B.A. (biochemistry) from Dartmouth College (Phi Beta Kappa, summa cum laude, with highest distinction). He matriculated to the Johns Hopkins University School of Medicine in 1978 and entered their Medical Scientist Training Program in Dr. Zarbin was awarded degrees in medicine (Alpha Omega Alpha) and pharmacology in He completed ophthalmology residency at the Wilmer Ophthalmological Institute in Dr. Zarbin completed fellowships in vitreoretinal surgery and in medical retinal disease at Wilmer and was an Assistant Chief of Service at Wilmer in Dr. Zarbin serves as Chair of the Institute of Ophthalmology and Visual Science, New Jersey Medical School, Chief of Ophthalmology at University Hospital in Newark, N.J., and is the Alfonse A. Cinotti, MD/Lions Eye Research Professor of Ophthalmology. Dr. Zarbin s research is focused on developing cell-based therapy for age-related macular degeneration. Dr. Zarbin is an Associate Editor of Investigative Ophthalmology and Visual Science and is a member of the Editorial Board of Survey of Ophthalmology. Dr. Zarbin is a Vice Chair of the Scientific Advisory Board of the Foundation Fighting Blindness and is an ex officio member of the National Advisory Eye Council of the National Institutes of Health.

12 11 ESASO 11th International AMD and Retina Congress Session 6 Other retinal challenges Chairs: Prof. Borja Corcóstegui, Spain and Prof. Antonio Capone, USA AMD, DME and BRVO/CRVO predominate as the clinically relevant macular pathologies, Though less common, the clinical entities addressed in this section present unique diagnostic and management challenges. In some instances, they are variants or complications of AMD. Alternatively, they may need to be distinguished from the more common conditions as prognosis and treatment differ. This section addresses some of the most important of these entities in an attempt to stimulate the discussion with panellists and audience. Borja Corcóstegui Instituto de Microcirugía Ocular, Barcelona, Spain Borja Corcóstegui is currently the Medical Director of the Instituto de Microcirugía Ocular in Barcelona, Spain. He graduated as an ophthalmologist from the Autonomous University of Barcelona (UAB) in 1977 after which he was an Associate Doctor at the Ciudad Sanitaria Vall d Hebrón. Subsequently he completed a Fellowship at the Wills Eye Institute in Philadelphia, Pennsylvania, USA. Professor Corcóstegui undertook various posts at the Ciudad Sanitaria Vall d Hebrón and the UAB until he founded the Instituto de Microcirugía Ocular in He is a peer reviewer for several national and international journals and has published in numerous European and American journals as well as authoring 3 books. Professor Corcóstegui has previously been President of the Sociedad Española de Retina y Vitreo (SERV) and EURETINA. He is a member of 15 national and international scientific societies and associations. Antonio Capone Associated Retinal Consultants (ARC), Royal Oak, Michigan, USA Dr Capone is an internationally recognized clinician, surgeon and educator. His special interests include paediatric vitreoretinal diseases, complicated retinal detachment, ocular oncology and macular disease. He has authored/co-authored over 200 publications in peer-reviewed medical journals, book chapters and publications from NCTs. His research interests encompass both paediatric and adult retinal disorders, including participation in industry-sponsored and National Eye Institute-sponsored trials. He has been actively involved in resident and fellowship education for 20 years, has served on the Ophthalmology Knowledge and Assessment Program Committee for the AAO and as an examiner for the American Board of Ophthalmology. Dr Capone joined Associated Retinal Consultants (ARC) in Royal Oak, Michigan in He is a Clinical Professor of Biomedical Sciences at Oakland University William Beaumont Hospital School of Medicine, Professor at the European School for Advanced Studies in Ophthalmology, Lugano, Switzerland and Co-Director of the ARC Vitreoretinal Fellowship Training Program. Dr Capone has been named in America s Who s Who in Medicine, The Best Doctors in America and The Best Doctors in the Southeast. He is a member of many professional organizations (including the AAO, American College of Surgeons, Macula Society, Club Jules Gonin, ARVO and International Society for Eye Research) and serves on the Executive Committee of both the American Society of Retina Specialists and the Retina Society.

13 ESASO 11th International AMD and Retina Congress 12 Faculty Luis Arias Bellvitge University Hospital, Barcelona, Spain Luis Arias is a vitreoretinal specialist at Bellvitge University Hospital in Barcelona since He did an observership at the Bascom Palmer Eye Institute in Miami. He is Associate Professor of Ophthalmology at the University of Barcelona. His main areas of interest are AMD, pathologic myopia, diabetic retinopathy, RVO, macular surgery and retinal detachment. He has published extensively in peer-reviewed journals such as Ophthalmology, Retina and British Journal of Ophthalmology. He has also authored many book chapters on the subject of maculopathies. He is the editor of a recent book on the subject of anti-vegf therapy. He has participated in many clinical trials evaluating PDT and antiangiogenic drugs for the management of different macular disorders. He is on the Editorial Board of the journal Archivos de la Sociedad Española de Oftalmología and is a Board Member of the SERV (Spanish Society of Retina and Vitreous). Maurizio Battaglia Parodi Scientific Institute San Raffaele Milan, Italy Dr Maurizio Battaglia Parodi is currently working at the Department of Ophthalmology, Scientific Institute San Raffaele, Milan. He had previous appointments at the Departments of Ophthalmology of the University of Trieste and Udine. Dr Parodi s major clinical and research interests include age-related macular degeneration, vascular diseases, and dystrophies. He has been a participant in many international clinical trials. He has authored over 100 scientific articles that appeared in peer-reviewed literature and 3 books. Dr Parodi has received awards for his scientific activity and is reviewer for many international journals. Francesco Boscia Department of Ophthalmology, Bari University, Bari, Italy Francesco Boscia, MD, is an Associate Professor at the Department of Ophthalmology at Bari University, Bari, Italy. His clinical interests are in diseases and surgery of the retina and vitreous. He received his medical degree from Bari University in 1986, completed his general ophthalmology residency at the same university in 1991 and undertook a vitreoretinal fellowship at King s College Hospital and Moorfields Eye Hospital in London, UK, in He has authored over 45 peer-reviewed papers.

14 13 ESASO 11th International AMD and Retina Congress Susan B Bressler Wilmer Eye Institute, John Hopkins University School of Medicine, Baltimore, MD, USA Susan Bressler graduated from Smith College, Northampton, MA, USA, Summa Cum Laude in She completed an internship in internal medicine at Johns Hopkins Hospital, Baltimore, MD, USA, followed by an ophthalmology residency at Harvard Medical School s Massachusetts Eye and Ear Infirmary, Boston, MA, USA. After a fellowship in medical retina at the Wilmer Eye Institute at Johns Hopkins Hospital and additional retinal surgery training at the Massachusetts Eye and Ear Infirmary, Dr Bressler joined the faculty at the Wilmer Eye Institute. In 2004, she was inducted as the inaugural recipient of the Julia G. Levy, PhD, Professor of Ophthalmology. In addition to her large referral practice, Dr Bressler has also published 190 peer-reviewed articles and 54 book chapters. She has been an Editorial Board member of the American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, The Johns Hopkins Medical Letter: Health After 50 and the Wilmer Retina Update. Dr Bressler s main research interests focus on collaborative efforts in clinical trials, including roles as Principal Investigator in several clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular AMD and all aspects of diabetic retinopathy. Dr Bressler has received numerous awards in the field of ophthalmology including the Rosenthal Award from the Macula Society, the Olga Keith Wiess Scholar Award from Research to Prevent Blindness, a Senior Achievement Award from the American Academy of Ophthalmology, a Senior Honor Award from The American Society of Retina Specialists and the Gertrude Pyron Award for Lifetime Achievement of Outstanding Research. She has given several named lectures throughout the US and has been invited to speak at numerous national and international meetings. Ângela Carneiro Hospital São João, Porto, Portugal Ângela Carneiro is a Retinal Specialist and Consultant of Ophthalmology at the Department of Ophthalmology, Hospital S. João, Porto, and Professor of the Department of Ophthalmology of the Faculty of Medicine, University of Porto, Porto, Portugal. Her main scientific area of research is CNV but she is also interested in angiogenesis, diabetic retinopathy and medical retina. Dr Carneiro is involved in a number of clinical trials as Principal Investigator/Co-Investigator, covering areas such as neovascular AMD, CNV and DME. She is a member of EURETINA and ARVO and has published a number of original papers in journals such as Retina, Experimental Eye Research, Journal of Cell Biochemistry, Acta Ophthalmologica and Ophthalmologica. Carl Claes Vitreoretinal Department, St Augustinus Hospital, Antwerp, Belgium Carl Claes is the Head and Founder of the Vitreoretinal Department at the St Augustinus Hospital in Antwerp, Belgium. In 1989 he founded the Vitreoretinal Course in Antwerp, which he continues to organize biannually for several hundred retinal specialists from across the world. Dr Claes carries out ~1200 surgical interventions annually, a large percentage of which are for international patients. He specializes in trauma, advanced diabetic retinopathy and proliferative vitreoretinopathy in addition to other areas. As well as developing new surgical instrumentations and techniques in collaboration with various medical companies, Dr Claes also travels extensively to demonstrate live surgical procedures. He has given more than 400 invited lectures across the world, received several international awards and is an active peer reviewer for a number of international journals.

15 ESASO 11th International AMD and Retina Congress 14 Bora Eldem Hacettepe Üniversitesi, Ankara, Turkey Bora Eldem is Professor of Ophthalmology at the Faculty of Medicine at Hacettepe University, Ankara, Turkey. Professor Eldem s main fields of interest are the medical and surgical treatments of vitreoretinal disorders, electrophysiology, uveitis and, especially, Behçet s disease. He has been involved in several RCTs such as EXCITE and RESTORE as Country Coordinator and Principal Investigator. Professor Eldem is a country delegate of the Union of European Medical Specialists and the European Board of Ophthalmology. He is also a member of various societies, including EURETINA, EVRS, ARVO and ASRS. Bruno Falcomatà Ophthalmic Operating Centre, BMM Hospital, Reggio Calabria, Italy Bruno Falcomatà is Head of the Unit of Retinal Diseases at Azienda Ospedaliera Bianchi-Melacrino-Morelli in Reggio Calabria, Italy. Dr Falcomatà completed his General Ophthalmology Residency and his Medical Retina Fellowship training at the Department of Ophthalmology of the San Raffaele Scientific Institute in Milan, Italy. His main clinical interest is in the diagnosis and treatment of AMD and diabetic retinopathy. He is co-author of two book chapters and he has published a number of scientific publications in national and international journals including AKT Augenheilk, British Journal of Ophthalmology, Graefe s Archive for Clinical and Experimental Ophthalmology and Investigative Ophthalmology and Visual Science. José García-Arumí Autonomous University of Barcelona, Barcelona, Spain José García-Arumí is Full Professor of Ophthalmology and Secretary of Surgery at the Autonomous University of Barcelona and Chairman of the Ophthalmology Department at the University Hospital, Valle de Hebrón, Barcelona. Professor García-Arumí is also a member and co-founder of the Instituto de Microcirugía Ocular in Barcelona. He holds the positions of Secretary of the Sociedad Española de Retina y Vítreo (SERV) and Liaison Leader for Europe of the ASRS. Professor García-Arumí collaborates on projects with the CIBER group to investigate the pathophysiology of diabetic retinopathy as well as collaborating with the EUCONDOR diabetes project. He has written over 160 publications and 38 book chapters in the field of ophthalmology. Professor García-Arumí sits on the Editorial Board for European Journal of Ophthalmology and Archivos de Sociedad Española de Oftalmología and is a reviewer for Retina, Ophthalmology, Archives of Ophthalmology and British Journal of Ophthalmology.

16 15 ESASO 11th International AMD and Retina Congress Alain Gaudric Department of Ophthalmology, Lariboisiere Hospital, Paris, France Alain Gaudric, MD is Professor of Ophthalmology and served as Chairman of the Department of Ophthalmology, at the Lariboisière Hospital, University of Paris 7 Denis Diderot, from 1993 to He is a member of the Club Jules Gonin of which he has been a member of the Committee, the Macula Society, the American Academy of Ophthalmology, the French Ophthalmological Society and he is a member of the Board of the European Society of Retina Specialists (EURETINA). Dr Gaudric has received the prize of the Retinal Research Foundation 2006 for his Jules Gonin lecture. He served in the Ophthalmology section of the French National Council of Universities, and is involved in the teaching program for the residents in Ophthalmology. Dr. Gaudric s clinical and research interests focus on retinal diseases, with a particular emphasis on macular surgery, retinal vascular diseases and retinal imaging. He published about 200 articles in peer reviewed journals as well as several book chapters and edited 2 books. He serves as a member of the Editorial Board of the American Journal of Ophthalmology, of Ocular surgery laser and imaging and of the Journal français d Ophtalmologie. Dr Gaudric has a particular interest in clinical trials and serves as principal investigator for many multicenter clinical trials in retinal vascular disease, age-related macular degeneration and macular surgery. Dr Gaudric has been an invited speaker at numerous national and international conferences on a wide range of rmedical and surgical topics. Giuseppe Guarnaccia Ophthalmic Operating Centre, BMM Hospital, Reggio Calabria, Italy Giuseppe Guarnaccia is Director III of the Surgery Department and Director of the Ophthalmic Operating Centre at the BMM Hospital in Reggio Calabria, Italy. He graduated in Medicine and Surgery from the University of Messina in 1977 with a Specialisation in Ophthalmology completed at the Scientific Hospital S. Raffaele in Milan in He became the Director of the Social Ophthalmic Centre of the Civil Hospital in Paola-Cetraro in 1993 followed by the position of Coordinator, and later Director, of the Ophthalmic Operative Centre. Dr Guarnaccia took up his initial post at the BMM Hospital in Dr Guarnaccia is a member of numerous Italian and international ophthalmological societies and has organised 10 international congresses of ophthalmology. He is also the recipient of various honours including the National AVIS Prize and the National IARVO Prize. Peter K Kaiser Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA Peter K. Kaiser, M.D. is a Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine. He graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute at the Cleveland Clinic, Cleveland, Ohio. As a NIH-funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in AMD and diabetic retinopathy. In addition, Dr Kaiser is actively involved in clinical research as Study Chairman of 7 major, multi-center, international clinical trials, and principal investigator in over 35 trials evaluating new treatments for AMD, diabetic retinopathy, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR), which is the OCT coordinating center for over 45 multi-center, clinical trials. Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored four textbooks, and more than 200 peer-reviewed papers. He is Editor-in-Chief of Current Concepts in Retina, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today, Retinal Physician, and Ocular Surgery News. Dr. Kaiser has been recognized by the AAO and American Society of Retina Specialists with Senior Achievement Awards, and is listed as one of the Best Doctors in America. He is the team ophthalmologist for the Cleveland Browns (National Football League), Cleveland Cavaliers (National Basketball Association), and the Cleveland Indians (Major League Baseball).

17 ESASO 11th International AMD and Retina Congress 16 Gabriele Lang University Eye Hospital Ulm Ulm, Germany Gabriele Lang, MD, is Professor of Ophthalmology at the Department of Ophthalmology at the University Eye Hospital Ulm, Ulm, Germany. She is Director of the Section of Medical Retina and Laser Treatment. She qualified from the Medical School at the University Erlangen-Nürnberg, Germany. She trained in Ophthalmology at the Department of Ophthalmology, University Erlangen-Nürnberg and completed a fellowship at the Wilmer Eye Institute, Johns Hopkins University Hospital, Baltimore, MD, USA. Professor Lang s major clinical interest is diagnosis and treatment of retinal diseases. Her major research fields are preclinical and clinical studies concerning diabetic retinopathy and AMD. She is currently a member of the Executive Committee of the German Society of Ophthalmology. She was president of the German Society of Ophthalmology from 2001 to She was President of the German Initiative Group Of Early Detection Of Diabetic Eye Disease (IFDA) from 2003 to 2007 and Vice President of the German Retinological Society from 2004 to She was Scientific Programme Director of the World Ophthalmology Congress 2010, in Berlin, Germany. Since 2002, Professor Lang has been Chief Editor of Klinische Monatsblätter für Augenheilkunde, the oldest ophthalmological journal. She has authored and co-authored over 170 articles in peer-reviewed journals, has written several book chapters and has published a book on diabetic retinopathy. She is the Principal Investigator and Investigator in several clinical trials and member of advisory boards, steering committees and safety committees. Paolo Lanzetta University of Udine, Udine, Italy Paolo Lanzetta is Associate Professor at the Department of Ophthalmology at the University of Udine, Italy. His main areas of activity are laser applications in ophthalmology; diagnosis and treatment of vitreous, retinal and macular diseases; and cataract surgery. Professor Lanzetta is actively involved in retinal clinical research and is currently an investigator in many international, multicentre clinical trials on PDT, anti-angiogenic and newer drugs and delivery systems. With surgical experience in anterior and posterior segment procedures and laser treatments, Professor Lanzetta has given over 350 presentations at national and international meetings. He is a member of numerous professional societies, including ARVO and the Macula Society. As well as publishing over 170 original articles, Professor Lanzetta is a scientific reviewer for many journals and serves on the Editorial Board of the European Journal of Ophthalmology. Won Ki Lee Seoul St. Mary s Hospital, Seoul, South Korea Won Ki Lee is Professor of the Department of Ophthalmology at Seoul St. Mary s Hospital in Seoul, South Korea. He is currently Principal Investigator in the Posurdex trial in DME (Allergan), the EVEREST study (Novartis) and the VIEW 2 study (Bayer Schering Pharma). Professor Lee is a member of the Korean Medical Association, the Korean Ophthalmological Society, the ASRS and EURETINA, and is the current Secretary General of the Korean Ophthalmological Society. He has published numerous articles on subjects such as PCV, subfoveal CNV, PDT, diabetic retinopathy and myopia in journals such as the Journal of the Korean Ophthalmological Society, the Japanese Journal of Ophthalmology, Retina and the American Journal of Ophthalmology. He has given many presentations on the subject of PCV, PDT, CSC and CNV at many international and national meetings.

18 17 ESASO 11th International AMD and Retina Congress Jordi Monés Institut de la Macula i de la Retina, Barcelona, Spain Dr Monés is an MD ophthalmologist, macula and vitreoretinal specialist, and a macular and retinal degeneration researcher. After graduating in Medicine and Surgery from the University of Barcelona, Barcelona, Spain, he specialized in Ophthalmology via MIR at the Centro de Oftalmología Barraquer, followed by 3 years of further training abroad including a Research Fellowship on the Retina at the Massachusetts Eye and Ear Infirmary at Harvard University, Boston, MA, USA, and a Clinical Fellowship programme at the Hospital San José at the Monterrey Institute of Technology and Higher Education, Monterrey, Mexico. On his return to Barcelona, he continued his clinical and research activities at the Hospital Dos de Maig de la Creu Roja and at the Instituto de Microcirugía Ocular de Barcelona (IMO) until He is currently the Director of the Institut de la Màcula i de la Retina, where he is exclusively devoted to the treatment of and research into diseases of the macula, retina and the vitreous. His interests encompass several areas of ocular diseases, including exudative and dry AMD, retinal transplant and vitreoretinal and macular surgery. Dr Monés is closely involved in most of the clinical trials conducted in international centres for the treatment of AMD and is currently involved in a number of phase II and III clinical trials. His work has been widely published in scientific journals and specialized books, and he has given more than 200 talks at international conferences and congresses. He is a member of 12 scientific societies, including the Macula Society, the Retina Society, the ASRS, the AAO, the ARVO, the European Vision Institute, Euretina and the European Association for Vision and Eye Research (EVER). Rafael Navarro Instituto de Microcirugía Ocular de Barcelona (IMO), Barcelona, Spain Rafael Navarro graduated from the Universitat Autònoma de Barcelona and completed his ophthalmology residency at the Hospital Vall d Hebron in Barcelona, Spain. Afterwards, he worked in two of the main public hospitals in Barcelona Hospital de Sant Pau and Hospital Clínic and joined the Instituto de Microcirugía Ocular in Dr Navarro s clinical practice focusses on medical retina, particularly macular diseases and hereditary retinal dystrophies. He is actively involved in various international multicentric clinical trials regarding AMD and DME. Athanasios Nikolakopoulos Papanikolaou Hospital, Thessaloniki, Greece Dr Nikolakopoulos is currently Chairman of the Ophthalmological Department of Papanikolaou Hospital, Thessaloniki,Greece, and holds the positions of President of the Greek Vitreo-Retinal Society (GVRS) and Former President of the Greek Ophthalmological Federation. He is also the principal organizer of the Thessaloniki Vitreo-Retinal School (TVRS) and is a member of the teaching faculty of ESASO.

19 ESASO 11th International AMD and Retina Congress 18 Ian Pearce Royal Liverpool University Hospital, Liverpool, United Kingdom Ian Pearce is a Consultant vitreo-retinal surgeon at St Paul s Eye Unit, Royal Liverpool University Hospital and Honorary Lecturer at the University of Liverpool. Mr Pearce s specific role is to combine both the medical and surgical approach to retinal disorders, including AMD, diabetic eye disease and inflammatory eye disease. Mr Pearce also provides a Supra-Regional Service for AMD and acts as a Regional Specialist Service for vitreoretinal surgery and uveitis. Mr Pearce is President of the Ophthalmic Imaging Society (UK) and Chair of the Advisory Committee on Dangerous Pathogens TSE Ophthalmic Sub-group. Mr Pearce also acts as an Expert Advisor to the CJD Incidents Panel. As well as being a member of the Scientific Committee of Royal College of Ophthalmologists, he is also an examiner for the Royal College of Ophthalmologists and Deputy Programme Director for Ophthalmology in Merseyside. Mr Pearce is the Principal/Co-investigator for several multi-national, randomized controlled trial studies in AMD, diabetic maculopathy, RVO, uveitis and retinal surgery. In addition, Mr Pearce has authored over 35 peer-reviewed articles and 3 national guidelines. David E Pelayes Center of Applied Research and Ophthalmological high, Maimonides University, Buenos Aires, Argentina David E Pelayes is Associate Professor of Ophthalmology at the School of Medicine, University of Buenos Aires and Maimonides University, Buenos Aires, Argentina. After graduating from the University of Buenos Aires in 1990, Dr Pelayes completed his residency at the Hospital José de San Martín and subsequent postgraduate studies of the retina and vitreous at the Hospital Carlos G. Durand. He gained his doctoral from the University of Buenos Aires in He is currently the Executive Director of the Pan American Society of Ocular Oncology and the General Secretary of EuroLam as well as being on the executive committee of a number of other national and international ophthalmology societies (ISOT, SAOO, APTS). Dr Pelayes has authored and edited chapters in the field of the retina, vitreous and ocular oncology as well as contributing to 193 publications. He is also on the editorial committee of Vision Pan America and the British Journal of Ophthalmology and is a reviewer for a number of other journals (Eye, Grafes Arch Clin Experiment Ophthalmol, Arch Soc Esp Oftalmol). Dr Pelayes has received 17 national and international awards. Giuseppe Querques Université Paris XII Paris, France Giuseppe Querques, MD, PhD, is Associate Professor at the Université Paris-Est Créteil, and Consultant Surgeon Ophthalmologist at the Créteil Eye Clinic, Créteil, France. He earned his MD degree from the University of Bari, Bari, Italy, and completed his ophthalmology residency and PhD at the University of Foggia, Foggi, Italy. Dr Querques completed medical fellowships at the Retina Associates of New Jersey, NJ, USA, the University Eye Clinic, Inselspital, Bern, Switzerland, and the Créteil Eye Clinic His main topics of interest are medical retina (AMD, retinal vascular diseases, inherited macular and retinal dystrophies) and ophthalmic surgery (retina and cataract). Dr Querques has contributed to more than 100 peer-reviewed articles published mainly in the areas of medical retina, and is a scientific reviewer for several international peer-reviewed journals (including Ophthalmology, Retina and the British Journal of Ophthalmology). His current main area of both clinical and laboratory research is the diagnosis (imaging) and treatment of retinal diseases. Dr Querques is the recipient of the 2005 prize of the International Agency for the Prevention of Blindness (IAPB) and the 2008 prize of the SOE. He is also a member of the AAO, ARVO and Retina Society among other ophthalmology societies.

20 19 ESASO 11th International AMD and Retina Congress Rufino Silva University Hospital of Coimbra, Coimbra, Portugal Rufino Silva is Assistant Professor of Ophthalmology at the University of Coimbra and Senior Consultant of Ophthalmology at the University Hospital of Coimbra, Coimbra, Portugal. He is also an Investigator at the Association for Innovation and Biomedical Research on Light and Image in Coimbra. Professor Silva s main fields of interest are AMD, myopia, vein occlusion, diabetic retinopathy and CNV. Leonidas Zografos Hospital Jules Gonin, Lausanne, Switzerland Leonidas Zografos, MD, is Professor and Chairman at the Faculty of Biology and Medicine of the University of Lausanne, Lausanne, Medical Director of the Jules Gonin Eye Hospital, Lausanne, and Scientific Director of the Institute for Research in Ophthalmology of Sion, Valais, Switzerland. His research activities and clinical practices are focussed mainly on the diagnosis and conservative management of ocular tumours as well as the development of pioneering radiotherapy techniques in ophthalmology. In 1984, he introduced the proton beam irradiation in western Europe for the treatment of intraocular tumours and significantly contributed to the development and the diffusion of this therapeutic technique in Europe, where this therapeutic modality has became particularly popular. Dr Zografos has an international reputation in the field of ocular oncology and has received numerous honours and distinctions. In 2009, he was nominated Commander of the Phoenix Legion of the Hellenic Republic. He is a regular member of several national and international ophthalmological scientific societies. He has authored or co-authored over 150 original articles and 132 book chapters, reviews or letters and he was the principal author and editor of the 2002 annual report of the French Ophthalmological Society on intraocular tumours.

21 ESASO 11th International AMD and Retina Congress 20 Floorplan Room 5C Ex-Mex Auditorium 3+4 Ex-Mex Auditorium 1 Plenary Room 5B Ex-Mex Room 5A Ex-Mex Congress Secretariat Auditorium 2 Ex-Mex Exhibition Wi-Fi Posters Coffee Breaks CMES Lunch

22 21 ESASO 11th International AMD and Retina Congress Thank you from ESASO We would like to thank the main sponsors of this meeting, Novartis Pharma AG, for providing us with an unrestricted educational grant to allow such a great event to take place. Novartis Pharma AG has a long-established interest in the treatment of retinal diseases, having provided revolutionary therapies for over 10 years. The Session Chairs have made an exceptional contribution in their leadership of the scientific content of the meeting, including the development of the programme, liaising with Speakers in the preparation of their presentations. We would also like to offer them special thanks: as leading retina specialists, their expertise has been paramount in the preparation and execution of this meeting. We would also like to thank the Faculty for their dedication in delivering the presentations, chairing the overall meeting and the individual sessions and for sharing their knowledge during the Meet-the-Expert sessions. Their contribution throughout has been of the utmost quality and it is an honor to host so many talented retina specialists. Finally we would like to thank all the delegates for attending this meeting, and hope to see them all again at the 12th congress next year. Delegate countries Argentina Germany Netherlands South Africa Australia Greece Norway South Korea Austria India Oman Spain Canada Ireland Pakistan Sri Lanka China Israel Poland Sweden Cyprus Italy Portugal Switzerland Czech Rep. Japan Qatar Thailand Denmark Kuwait Romania Turkey Egypt Latvia Russia UAE Faroe Islands Lebanon Singapore UK Finland Lithuania Slovakia USA France Malaysia Slovenia

23 ESASO 11th International AMD and Retina Congress 22 Organisation Organising Committee President of the ESASO Foundation Dr. Giuseppe Guarnaccia, Italy Member of the ESASO Foundation Board Prof. Borja Corcóstegui, Spain Member of the ESASO Foundation Board Prof. Francesco Bandello, Italy Scientific Committee Chairman Prof. Francesco Bandello, Italy Co-Chairs Prof. José Cunha-Vaz, Portugal Prof. Neil M Bressler, USA Congress Organiser ESASO c/o Università della Svizzera italiana Via Giuseppe Buffi Lugano Switzerland General Manager Gabriella Skala Skala Communications GmbH, Switzerland Scientific Secretary Denise Etherington, Suzanne Smith Chameleon Communications, UK Professional Congress Organiser Luisa Marques, Isabel Oliveira, Joana Marques Meeting Point, Portugal Coordinators Dr. Maurizio Battaglia-Parodi, Italy Dr. Bruno Falcomatà, Italy We hope you enjoyed this year s congress, which we feel has offered further insight into the future of treating retinal diseases.